Comprehensive BioReference Compound Library

T. Matviyuk, I. Kos, O. Buhera, A. Iakovenko, P. Borisko, I. Komarov

Introduction and Aim

To address continuously growing interest to *Drug Repurposing* we designed and carefully collected a ***B***ioactive ***R***eference ***C***ollection of *1500 compounds* with extensive target classes coverage and the broadest possible therapeutic areas applications – from CNS agents and anti-infectives to anticancer drugs and steroids. Represented collection of carefully selected compounds includes **648** *FDA- approved drugs*, as well as **852** "*tool compounds*" with validated biological activity, active metabolites/prodrugs, and drug candidates that are currently undergoing clinical trials.

Additionally we provide *broad functionalization of Drugs* and relative actives with covalent warheads, biotin or/and dye-linking, PED-derivatization and other modifications. Versatile chemistry and the largest stock of valuable reagents enables Enamine to produce new derivatization of well known drugs.



Collection of FDA approved Drugs

Our collection of 648 approved drug compounds has been carefully collected and distilled with manual analysis to exclude supplements and natural amino acids from active synthetic substances and natural products derivatives. Quality of commercially available drug collection is a milestone of any screening campaign focused on Drug Repurposing or Signaling pathway investigation.



Fragments from Drugs

To bring valuable fragments into FBDD, we designed library of compounds with already validated structural motifs and cores presented in most essential approved drugs. Scaffold-based algorithm was applied to find most relevant structures and design the library of *5,300 Fragments from Drugs*.



Ready-to-use preplated compound Sets

To meet specific focused screening requirements we designed small libraries of biologically active compounds intended for application in certain therapeutic areas, protein classes or for target identification purposes.

- **Kinase Inhibitors** – 240 cmpds
- **GPCRs Inhibitors** – 160 cmpds
- **Ion Channel actives** – 90 cmpds
- **Proteases Inhibitors** – 80 cmpds
- **Clinical trails library** – 738 cmpds
- **Epigenetics** – 80 cmpds
- **CNS library** – 85 cmpds
- **Immunlogy library** – 80 cmpds



Our scientific team can also provide assistance in choosing compounds that are relevant to your research requirements.

*All compounds are of high assured purity 95%+, supported with all related data on activity type/target and indicated activity and solubility values.

Contact

Tatiana Matviiuk, PhD

t.matviyuk@enamine.net, Enamine Ltd, www.enamine.net
78 Chervonotkatska St, 02660 Kyiv, Ukraine